

Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

Information for the public

Published: 20 July 2022

www.nice.org.uk

Abemaciclib (Verzenios), taken with endocrine therapy, is available on the NHS as a possible adjuvant treatment (after surgery) for hormone receptor-positive, HER2-negative, node-positive early breast cancer. It is a possible treatment for adults whose cancer is at high risk of recurrence because it has spread into:

- at least 4 axillary (armpit) lymph nodes, or
- 1 to 3 axillary lymph nodes, and there is either grade 3 disease or the primary tumour size is at least 5 cm.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

- [Breast Cancer Now](#), 0808 800 6000
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4680-8